Lonafarnib

Pricing Availability   Qty
说明: Potent farnesyltransferase inhibitor
化学名: 4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide
纯度: ≥98% (HPLC)
说明书
引用文献 (1)
评论

生物活性 for Lonafarnib

Lonafarnib is a potent farnesyl transferase inhibitor (IC50 = 1.9 nM). Inhibits farnesylation of RAS. Also inhibits Pgp transport (IC50 < 3 μM) and increases potency and anticancer activity when used in conjunction with cytotoxic Pgp substrates. Inhibits neovascularization by affecting cell motility. Orally bioavailable.

技术数据 for Lonafarnib

分子量 638.82
公式 C27H31Br2ClN4O2
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 193275-84-2
PubChem ID 148195
InChI Key DHMTURDWPRKSOA-RUZDIDTESA-N
Smiles NC(N1CCC(CC1)CC(N2CCC([C@H]3C4=NC=C(C=C4CCC5=CC(Cl)=CC(Br)=C35)Br)CC2)=O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for Lonafarnib

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 6.39 10

制备储备液 for Lonafarnib

以下数据基于产品分子量 638.82。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.1 mM 15.65 mL 78.27 mL 156.54 mL
0.5 mM 3.13 mL 15.65 mL 31.31 mL
1 mM 1.57 mL 7.83 mL 15.65 mL
5 mM 0.31 mL 1.57 mL 3.13 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for Lonafarnib

分析证书/产品说明书
选择另一批次:

参考文献 for Lonafarnib

参考文献是支持产品生物活性的出版物。

Bowman et al (2015) Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer. Sci.Signal. 8 PMID: 25628462

Lo Cicero et al (2016) A high throughput phenotypic screening reveals compounds that counteract premature osteogenic differentiation of HGPS iPS-derived mesenchymal stem cells. Sci.Rep. 6 34798 PMID: 27739443

Sun et al (2015) Lonafarnib is a potential inhibitor for neovascularization. PLoS One. 10 e0122830 PMID: 25853815

Wang et al (2001) The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer.Res. 61 7525 PMID: 11606389

Nielsen et al (1999) Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res. 59 5896 PMID: 10606231

Shen et al (2015) Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. Drug Discov.Today. 20 267 PMID: 25450772


If you know of a relevant reference for Lonafarnib, please let us know.

按产品操作查看相关产品

查看全部 Protein Prenyltransferase Inhibitors

关键词: Lonafarnib, Lonafarnib supplier, Lonafarnib, SCH66336, farnesyl, transferase, inhibitors, inhibits, PgP, transport, anticancer, neovascularization, orally, bioavailable, Protein, Prenyltransferases, Post-translational, Modifications, 6265, Tocris Bioscience

1 篇 Lonafarnib 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Lonafarnib 的部分引用包括:

Daniel E et al (2022) Progerin-expressing endothelial cells are unable to adapt to shear stress. Biophys J 121 620-628 PMID: 34999130


您是否知道使用了 Tocris Lonafarnib 的优秀论文? 请告知我们.

Lonafarnib 的评论

目前没有该产品的评论。 Be the first to review Lonafarnib and earn rewards!

Have you used Lonafarnib?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review